NEWSROOM
News & Stories
Newsroom
Press Releases
Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients
Data from the I-SPY 2 trial showed the first long-term survival results for patients pre-selected as MammaPrint high-risk, with 94% of the patients who achieved pathological complete response event-free at three years MammaPrint assessment Read More
Agendia and UZ Leuven Partner to Co-Validate MammaPrint BluePrint Breast Cancer Risk of Recurrence and Molecular Subtyping Kit Ahead of European Launch
IRVINE, CA, AMSTERDAM, NETHERLANDS – 7 December 2017 – Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and University Hospitals Leuven (UZ Leuven) in Belgium have partnered to co-validate Agendia’s new in Read More
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint BluePrint Breast Cancer Kit Co-Validation Study
Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit IRVINE, CA, AMSTERDAM, and PARIS – 5 December 2017 – Read More